Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024
Rhea-AI Summary
Relay Therapeutics (Nasdaq: RLAY), a clinical-stage precision medicine company, has announced it will release its second quarter 2024 financial results and corporate highlights on Tuesday, August 6, 2024, after the U.S. financial markets close. The company, known for its innovative approach to drug discovery by combining advanced computational and experimental technologies, will provide insights into its financial performance and recent developments. This announcement is significant for investors and analysts tracking Relay Therapeutics' progress in the competitive biotech sector.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, RLAY declined 0.60%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report second quarter 2024 financial results and corporate highlights after the U.S. financial markets close on Tuesday, August 6, 2024.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.
Contact:
Megan Goulart
617-545-5526
mgoulart@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
When will Relay Therapeutics (RLAY) release its Q2 2024 financial results?
What is Relay Therapeutics' (RLAY) stock symbol and exchange?
What type of company is Relay Therapeutics (RLAY)?
